Avyxa Holdings

Avyxa is a clinical-stage biotechnology company focused on the discovery and development of novel anti-infective therapies, particularly for the treatment of HIV. The company's lead candidate, AVX-175, is a small-molecule maturation inhibitor that targets the HIV-1 Gag protein to prevent the formation of mature, infectious viral particles. Founded by a team of former Merck virology experts, Avyxa aims to address the needs of patients with multi-drug resistant HIV and those seeking simplified treatment regimens. The company's approach focuses on high-potency molecules with the potential for long-acting delivery. Avyxa is backed by leading life science investors and leverages deep expertise in viral replication to create next-generation antivirals.